FTRE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Fortrea Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Fortrea securities between July 3, 2023 and February 28, 2025, both dates inclusive (the 'Class Period'). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/FTRE.
Case Details
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings; (2) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (3) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; (4) accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (5) as a result, the Company's public statements were materially false and misleading at all relevant times.
What's Next?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/FTRE. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Fortrea you have until August 1, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
42 minutes ago
- Malaysian Reserve
INVESTOR ALERT: Investor Files Class Action Lawsuit Against Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund and Attorneys Announces Opportunity for I
SAN DIEGO, July 23, 2025 /PRNewswire/ — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund (the 'Easterly ROCMuni Fund') (NASDAQ: RMJAX; RMHVK; RMHIX) shares between May 5, 2023 and June 12, 2025, inclusive (the 'Class Period'), have until September 22, 2025 to seek appointment as lead plaintiff of the Easterly ROCMuni class action lawsuit. Captioned Victorson v. James Alpha Funds Trust d/b/a Easterly Funds Trust, No. 25-cv-06028 (S.D.N.Y.), the Easterly ROCMuni class action lawsuit charges the Easterly ROCMuni Fund, James Alpha Funds Trust d/b/a Easterly Funds Trust, investment adviser Easterly Investment Partners LLC and its former investment adviser Principal Street Partners, LLC, certain of the Easterly ROCMuni Fund's underwriters, certain of their top executive officers and trustees, and others with violations of the Securities Exchange Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the Easterly ROCMuni class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ CASE ALLEGATIONS: The Easterly ROCMuni Fund commenced operations in September 2017 and, as a mutual fund, it is subject to an extensive regulatory framework designed to safeguard the investing public. The 'Fact Sheet' for the Easterly ROCMuni Fund states that the Easterly ROCMuni Fund '[s]eeks to provide long-term, yield-driven total return relying mostly on fundamental credit analysis by building a diversified high-yield portfolio focusing on overlooked and under-appreciated sectors of the high-yield municipal bond market.' Unlike stocks, whose price is determined through trading on an exchange, mutual fund shares must be priced daily based on the fund's net asset value ('NAV'). The Easterly ROCMuni class action lawsuit alleges that defendants made false and/or misleading statements and/or failed to disclose that: (i) the Easterly ROCMuni Fund had marked tens of millions of dollars' worth of its portfolio assets at artificially inflated prices that did not reasonably reflect the fair value of those assets; (ii) the Easterly ROCMuni Fund had implemented a fundamentally flawed pricing and valuation methodology which had systematically inflated the Easterly ROCMuni Fund's NAV and individual asset valuations; (iii) the Easterly ROCMuni Fund was more heavily invested in illiquid assets than disclosed in its Offering Materials; (iv) the Easterly ROCMuni Fund's assets were more closely correlated and less diversified than disclosed in its Offering Materials; (v) as a result, the Easterly ROCMuni Fund's stated NAV, NAV per share, individual asset valuations, and historical performance were materially overstated; and (vi) consequently, the Easterly ROCMuni Fund was subject to a material undisclosed risk of a sudden collapse in the price of Easterly ROCMuni Fund shares. The Easterly ROCMuni class action lawsuit further alleges that on June 13, 2025, the Easterly ROCMuni Fund abruptly marked down the value of Easterly ROCMuni Fund shares by 30%. The per share NAV of RMHIX was marked down from $6.15 per share the prior day to $4.33 per share; the per share NAV of RMHVX was marked down from $6.19 per share the prior day to $4.36 per share; and the per share NAV of RMJAX was marked down from $6.13 per share the prior day to $4.31 per share. The value of Easterly ROCMuni Fund shares continued to plummet in subsequent days, falling to less than $3 per share within a span of just two weeks. The total net assets of the Easterly ROCMuni Fund collapsed from over $230 million as of March 31, 2025 to less than $17 million as of July 8, 2025. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Easterly ROCMuni Fund shares during the Class Period to seek appointment as lead plaintiff in the Easterly ROCMuni class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Easterly ROCMuni class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Easterly ROCMuni class action lawsuit. An investor's ability to share in any potential future recovery of the Easterly ROCMuni class action lawsuit is not dependent upon serving as lead plaintiff. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLPJ.C. Sanchez, Jennifer N. Caringal655 W. Broadway, Suite 1900, San Diego, CA 92101800-449-4900info@
Malaysian Reserve
42 minutes ago
- Malaysian Reserve
RXST INVESTOR ALERT: RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, July 23, 2025 /PRNewswire/ — The law firm of Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596 (C.D. Cal.) – seeks to represent purchasers or acquirers of RxSight, Inc. (NASDAQ: RXST) securities and charges certain of RxSight's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the RXSight class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ Lead plaintiff motions for the RXSight class action lawsuit must be filed with the court no later than September 22, 2025. CASE ALLEGATIONS: RxSight is a commercial-stage medical technology company that engages in the research and development, manufacture, and sale of light adjustable intraocular lenses ('LAL') used in cataract surgery. The RxSight class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) RxSight was experiencing 'adoption challenges' and/or structural issues resulting in declines in sales and utilization; (ii) defendants had overstated the demand for RxSight's products; and (iii) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025. The RxSight class action lawsuit further alleges that on July 8, 2025, RxSight reported preliminary second quarter of 2025 financial results, revealing significant declines in Light Delivery Device ('LDD') sales, LAL utilization, and overall revenue. RxSight also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint, and RxSight's CEO, defendant Ronald Kurtz, disclosed that '[a]doption challenges over the last few quarters have been a primary reason for the LDD stall,' according to the complaint. The RxSight class action lawsuit alleges that on this news, the price of RxSight stock fell nearly 38%. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired RxSight securities during the class period to seek appointment as lead plaintiff in the RxSight class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the RxSight class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the RxSight class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the RxSight class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLPJ.C. Sanchez, Jennifer N. Caringal655 W. Broadway, Suite 1900, San Diego, CA 92101800-449-4900info@
Malaysian Reserve
7 hours ago
- Malaysian Reserve
American Trust Investment Services Leads Cre8 Enterprise Ltd. IPO on Nasdaq
ATIS Underscores Commitment to Growth Companies in FinTech and Regulatory Technology Sectors NEW YORK, July 23, 2025 /PRNewswire/ — American Trust Investment Services, Inc. (ATIS) today announced that it served as lead underwriter for Cre8 Enterprise Ltd. (NASDAQ: CRE) in connection with its initial public offering. The offering consisted of 1,450,000 Class A ordinary shares at a public offering price of $4.00 per share, generating gross proceeds of approximately $5.8 million before underwriting discounts and offering expenses. Shares of Cre8 Enterprise Ltd. begin trading today on the Nasdaq Capital Market under the ticker symbol 'CRE.' Cre8 Enterprise Ltd., based in Hong Kong, is a leading provider of integrated financial printing and disclosure services. The company, founded in 2006, serves a diverse range of clients, including Hong Kong–listed companies, IPO applicants, and private enterprises. Its offerings include financial printing, typesetting, translation, logistics, e-submission services, and regulatory technology solutions, all supported by a 24/7 operating model. The net proceeds from the offering will support Cre8's continued investment in its regulatory technology platform, enhancement of printing and logistics capacity, and other general corporate purposes, as outlined in the company's registration statement. 'Helping Cre8 achieve this important milestone reinforces ATIS's role as a trusted partner to companies at the intersection of technology and financial services,' said Ian Lippy, Chief Operating Officer of ATIS. 'We are proud to support their journey to the public markets and look forward to seeing their continued success as a Nasdaq-listed company.' 'At ATIS, we focus on transactions that combine solid fundamentals with technology-led growth,' said James L. Clarren, Chief Compliance Officer and Head of Equity Capital Markets at ATIS. 'Cre8's leadership in financial printing and e-disclosure platforms positions it perfectly at the intersection of regulation and innovation.' This offering builds on ATIS's momentum in lead-managing high-impact transactions. The firm remains focused on serving mid-market growth companies with a hands-on execution model, regulatory insight, and institutional reach. About American Trust Investment Services, Inc. American Trust Investment Services, Inc. (ATIS) is a leading investment bank and financial services firm that provides tailored capital markets solutions for growth-driven companies. Headquartered in Chicago, with offices nationwide, ATIS offers investment banking, brokerage, and advisory services. Known for its hands-on approach, ATIS has guided companies through complex financial transactions with integrity, expertise, and consistent execution. For more information, visit Media & Company Contact:Ian E. LippyAmerican Trust Investment Services, Inc. (ATIS)media@
